Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Aberdeen pharmaceutical firm calls a halt to drug trial after ‘quality concerns’

Post Thumbnail

One of Aberdeen’s largest pharmaceutical companies has called a temporary halt to a clinical trial while it investigates “quality concerns” over its new drug for Crohn’s disease.

4D Pharma, which bases its research facilities at the University of Aberdeen’s Foresterhill Campus, said it has delayed the phase 1 trial for its Thetanix drug, which was set to be tested on live patients in the UK next week.

The new drug is aimed at treating Paediatric Crohn’s Disease (PCD). Crohn’s is a chronic inflammatory bowel disease that causes swelling, across the lining of the digestive tract. Up to one in five Crohn’s sufferers show symptoms before they are 20 years old, which raises risk of growth failure, malnutrition, delayed puberty and bone thinning.

The firm said the trial delay was taken as a “precautionary” measure after “concerns” emerged during manufacture of an additional batch of the drug. It expects the investigation to take about a month.

Last year, the company highlighted that the trial was “unusual” in that it would include only young patients with the disease.

Dr Alex Stevenson, the company’s Chief Scientific Officer said: “Although we are eager to progress our phase 1 trial in Paediatric Crohn’s Disease, we have taken the precautionary measure of delaying the dosing of patients until our investigation has been completed.
“Importantly all our other programmes are unaffected by this issue, and we remain on track to deliver new programmes into the clinic in 2016.”

He added that the company’s trial of another drug, Blautix, for the treatment of Irritable Bowel Syndrome (IBS), has completed. The company said it will reveal the results of the trial in the next few weeks.

4D Pharma grew out of GT Biologics, a spin out of Aberdeen University’s Rowett Institute of Nutrition and Health, led by gut immunology expert, Professor Denise Kelly.

Aquarius Equity Partners took an initial stake in GT Biologics in 2012, after which its name was changed to 4D Pharma.

The Leeds-based private equity firm, which specialises in life sciences, floated 4D the Alternative Investment Market (AIM) in February 2014, in a £16.6million IPO. The company joined the marked valued at £36.5million and has since rocketed to be worth 15 times more, almost £565million.

4D bought out the remaining investors in GT Biologics last year, paying £1.22million for a 16.5% stake.